Cargando…
Real‐world outcomes among patients with advanced or metastatic biliary tract cancers initiating second‐line treatment
BACKGROUND: Limited data are available regarding second‐line (2 L) treatment for advanced or metastatic biliary tract cancers (BTC) in the US real‐world setting. This study explores the rapidly evolving and growing treatment landscape in the 2 L setting for advanced or metastatic BTC with a large co...
Autores principales: | Cosgrove, David P., Reese, Emily S., Fulcher, Nicole M., Bobiak, Sarah S., Lamy, Francois‐Xavier, Allignol, Arthur, Boyd, Marley, Mahmoudpour, Seyed H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972013/ https://www.ncbi.nlm.nih.gov/pubmed/36263922 http://dx.doi.org/10.1002/cam4.5282 |
Ejemplares similares
-
Advanced or metastatic biliary tract cancer in Japan: a study using the Japan Medical Data Center payer claims database
por: Argoubi, Ramzi, et al.
Publicado: (2023) -
FOLFIRI as second-line treatment of metastatic biliary tract cancer patients
por: Caparica, Rafael, et al.
Publicado: (2019) -
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
por: Rizzo, Alessandro, et al.
Publicado: (2022) -
Immunotherapy in Biliary Tract Cancer: Worthy of a Second
Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020) -
Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)